臨床外科75巻8号

2020年08月発行

特集 遺伝性腫瘍とゲノム医療を学ぶ

ゲノム医療

MSI-high固形癌に対する免疫チェックポイント阻害薬治療と当院におけるMSI検査体制

著者： 緒方貴次¹ 成田有季哉¹ 室圭¹

所属機関： ¹愛知県がんセンター薬物療法部

ページ範囲：P.958 - P.966

文献概要

【ポイント】
◆MSI-highを有する固形癌は高い奏効割合と生存期間延長が期待されるため，二次治療までに免疫チェックポイント阻害薬が使用できる癌腫（食道癌など）以外では，検体がある場合には可能な限り検査に提出する．
◆治療期間が長期になり，免疫関連有害事象の出現が予想されるため，正確に検査を行うことと適正に診療を行うことが重要である．
◆MSI-highの場合は遺伝カウンセリングを考慮し，必要に応じて遺伝カウンセリング外来受診を提案する．そのためには，施設単位で患者フローを作成し，診断後速やかに受診を促せるような診療体制を整える必要がある．

参考文献

1）Li SKH, Martin A：Mismatch Repair and Colon Cancer：Mechanisms and Therapies Explored. Trends Mol Med 22：274-289, 2016

2）Eso Y, Shimizu T, Takeda H, et al：Microsatellite instability and immune checkpoint inhibitors：toward precision medicine against gastrointestinal and hepatobiliary cancers. J Gastroenterol 55：15-26, 2020

3）Le DT, Durham JN, Smith KN, et al：Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357：409-413, 2017

4）Marabelle A, Le DT, Ascierto PA, et al：Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer：Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 38：1-10, 2020

5）Le DT, Kim TW, Van Cutsem E, et al：Phase Ⅱ Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer：KEYNOTE-164. J Clin Oncol 38：11-19, 2020

6）Klingbiel D, Saridaki Z, Roth AD, et al：Prognosis of stage Ⅱ and Ⅲ colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status：results of the PETACC-3 trial. Ann Oncol 26：126-132, 2014

7）Sinicrope FA：DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer. Nat Rev Clin Oncol 7：174-177, 2010

8）Innocenti F, Ou F-S, Qu X, et al：Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. J Clin Oncol 37：1217-1227, 2019

9）Overman MJ, Bergamo F, McDermott RS, et al：Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high（dMMR/MSI-H）metastatic colorectal cancer（mCRC）：Long-term survival according to prior line of treatment from CheckMate-142. J Clin Oncol 36：554-554, 2018

10）Andre T, Lonardi S, Wong M, et al：Nivolumab ＋ ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high（dMMR/MSI-H）metastatic colorectal cancer（mCRC）：First report of the full cohort from CheckMate-142. J Clin Oncol 36：553-553, 2018

11）Ribic CM, Sargent DJ, Moore MJ, et al：Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349：247-257, 2003

12）Sargent DJ, Marsoni S, Monges G, et al：Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28：3219-3226, 2010

13）André T, De Gramont A, Chibaudel B, et al：MOSAIC Study：Actualization of Overall Survival（OS）with 10 Years Follow Up and Evaluation of Braf. By Gercor and Mosaic Investigators. Ann Oncol 25：iv169, 2014

14）Gavin PG, Paik S, Yothers G, et al：Colon cancer mutation：prognosis/prediction--response. Clin Cancer Res 19：1301, 2013

15）Zaanan A, Shi Q, Taieb J, et al：Analysis of DNA mismatch repair（MMR）and clinical outcome in stage III colon cancers from patients（pts）treated with adjuvant FOLFOX ＋/− cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials. J Clin Oncol 33：3506-3506, 2015

16）Polom K, Marano L, Marrelli D, et al：Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. Br J Surg 105：159-167, 2018

17）Cho J, Kang SY, Kim KM：MMR protein immunohistochemistry and microsatellite instability in gastric cancers. Pathology 51：110-113, 2019

18）Janjigian YY, Sanchez-Vega F, Jonsson P, et al：Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. Cancer Discov 8：49-58, 2018

19）Janjigian YY, Bendell J, Calvo E, et al：CheckMate-032 Study：Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. J Clin Oncol 36：2836-2844, 2018

20）Pietrantonio F, Miceli R, Raimondi A, et al：Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. J Clin Oncol 37：3392-3400, 2019

21）日本癌治療学会，日本臨床腫瘍学会（編）：成人・小児進行固形がんにおける臓器横断的ゲノム診療のガイドライン第2版．金原出版，2019